Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
The purpose of this study is to investigate whether improved radiation planning technology that conforms to the shape and size of the cancer, can be used to treat multiple sites of cancer within the brain, and at the same time protect and preserve your brain (memory and cognitive) function. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with 3-10 measurable cerebral metastases, i.e. your cancer has spread to three or more spots on the brain. Study details: All participants in this study will receive a new treatment called Hypofractionated Stereotactic Radiotherapy. This is highly focused radiation given in one or a few (5-6) treatments. Robotic targeting is used to avoid important parts of the normal brain. Where previous treatment for multiple sites of cancer within the brain has involved giving radiation to the whole brain, this treatment will allow us to treat multiple areas at the same time. The aim is to avoid the use of whole brain radiation that can affect the memory structures within the brain such as the hippocampus, thus preserving brain (memory and cognitive) function. The trial will use software called "BrainLab Elements (Trademark)". This software will help the radiation oncologist to plan and deliver the radiotherapy treatment. All participants will be monitored throughout treatment for safety. They will also be asked to undergo MRI scans and complete some questionnaires at the start of the study and at 3 and 6 months after treatment to assess neurocognitive functioning, disease response, and quality of life. We estimate that this study will contribute further to the research into using radiotherapy to control cancers that have spread to the brain, while minimising the effects on brain function.
Conditions
This trial is treating people with advanced cancer that has spread to the brain
Eligibility
Inclusion
- • Pathological evidence of a known non-haematological malignancy within 5 years of enrolment.
• Three to ten metastatic brain lesions or surgical cavities which correlate with the confirmed non-haematological malignancy.
• Total Planning Target Volume <15cc for single or three fraction treatment and <35cc for fractionated treatment (five fractions).
• Largest single Planning Target Volume of unresected disease <10cc
• Largest single Planning Target Volume of a resection cavity <15 cc
• Age >18years
• Participants 60 years of age or older must nominate a friend or relative whom will participate in the cognitive decline questionnaire sub-study.
• Must be sufficiently proficient in English to complete neuropsychology tests
Exclusion
• Cognitive impairment which may interfere with ability to participate in the neurocognitive assessments
• Untreated clinically significant hydrocephalus
• Haematological, Small cell, Germ Cell malignancy or unknown primary tumour
• Leptomeningeal disease
• Multiple new cranial nerve deficits in the absence of overt intracranial disease
• Prior cranial irradiation which would compromise safety if overlapped with protocol treatment
• Contra-indication for MRI and gadolinium contrast use:
o Participants with a known risk of poor renal function must have an estimated Glomerular Filtration Rate >50 millilitres per minute
o Known hypersensitivity to Gadolinium contrast
o Non-MRI compatible VP shunt/surgical apparatus
o Pacemaker/cardiac defibrillator not MRI compatible
• Contra-indications to steroid support (e.g. active peptic ulceration or previous steroid psychosis)
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:
Trial sponsor
Intergrated Clinical Oncology Network Pty Ltd (ICON)
Scientific Title
A Phase II Prospective Trial of Stereotactic Hypofractionated Radiation for Multiple (3-10) cerebral metastases including Neurological and Cognitive assessment
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information